Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Jonathan A. Gill"'
Publikováno v:
International Journal of Nuclear Security, Vol 2, Iss 3 (2016)
Deterring nuclear terrorism is a critical national asset to support the preclusion of non-state actors from initiating a nuclear attack on the United States. Successful attribution of a detonated nuclear weapon allows for timely responsive measures t
Externí odkaz:
https://doaj.org/article/6648312b5ad944b48935c4aa552d9305
Autor:
Long Dao, Dristhi Ragoonanan, Izhar Batth, Arun Satelli, Jessica Foglesong, Jian Wang, Wafik Zaky, Jonathan B. Gill, Diane Liu, Aisha Albert, Nancy Gordon, Winston Huh, Douglas Harrison, Cynthia Herzog, Eugenie Kleinerman, Richard Gorlick, Najat Daw, Shulin Li
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDespite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as < 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such,
Externí odkaz:
https://doaj.org/article/ecabc7e1fe53496c97da19405d1ff875
Autor:
Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
Clinical Cancer Research. 29:1708-1718
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to invest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78f23ea3e8e64341e0552b9d54de1861
https://doi.org/10.1158/1078-0432.ccr-22-3629
https://doi.org/10.1158/1078-0432.ccr-22-3629
Autor:
Dristhi Ragoonanan, Sajad J. Khazal, Rodrigo Mejia, Linette Ewing, Jean-Bernard Durand, Lara Bashoura, Jean Tayar, Natalie Dailey Garnes, Demetrios Petropoulos, Priti Tewari, Micah Bhatti, Ali Haider Ahmad, Jose Cortes, Shehla Razvi, Katrina McBeth, Rita Swinford, Basirat Shoberu, Waseem Waseemuddin, Linda Chi, Jonathan B. Gill, Wafik Zaky, Najat Daw, Cristina Gutierrez, Welela Tereffe, Partow Kebriaei, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin, Kris M. Mahadeo
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavi
Externí odkaz:
https://doaj.org/article/7cfc638f4d744cde9c9a56cf232f8f52
Autor:
Pooja Hingorani, Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Wei-Lien Wang, Michael E. Roth, Yifei Wang, Jonathan B. Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory Gatto, Edward A. Kolb, Malcolm A. Smith, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick
Publikováno v:
Molecular Cancer Therapeutics. 21:1318-1325
HER2 is expressed in many pediatric solid tumors and is a target for innovative immune therapies including CAR-T cells and antibody–drug conjugates (ADC). We evaluated the preclinical efficacy of trastuzumab deruxtecan (T-DXd, DS-8201a), a humanize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89ef07eefc04e611e6cccfc8944ec07e
https://doi.org/10.1158/1535-7163.mct-21-0758
https://doi.org/10.1158/1535-7163.mct-21-0758
Autor:
Vivek Subbiah, Funda Meric-Bernstam, Richard Gorlick, Nelson Hamerschlak, Anthony P. Conley, Joseph A. Ludwig, Neeta Somaiah, J. Andrew Livingston, Shreyaskumar R. Patel, Christina L. Roland, Valerae O. Lewis, Douglas J. Harrison, Jonathan B. Gill, Najat Daw, Wei-Lien Wang, Alexander J. Lazar, Robert S. Benjamin, Vinod Ravi, Ravin Ratan, Maria A. Zarzour, Shubham Pant, Apostolia M. Tsimberidou, Daniel D. Karp, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Siqing Fu, Cynthia E. Herzog, Aung Naing, David S. Hong, Shiraj Sen, Jason Roszik, Justin T. Moyers, Roberto Carmagnani Pestana
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff57d97d02e8e004b84f0db0adb9a0a
https://doi.org/10.1158/1078-0432.22634420.v1
https://doi.org/10.1158/1078-0432.22634420.v1
Autor:
Vivek Subbiah, Funda Meric-Bernstam, Richard Gorlick, Nelson Hamerschlak, Anthony P. Conley, Joseph A. Ludwig, Neeta Somaiah, J. Andrew Livingston, Shreyaskumar R. Patel, Christina L. Roland, Valerae O. Lewis, Douglas J. Harrison, Jonathan B. Gill, Najat Daw, Wei-Lien Wang, Alexander J. Lazar, Robert S. Benjamin, Vinod Ravi, Ravin Ratan, Maria A. Zarzour, Shubham Pant, Apostolia M. Tsimberidou, Daniel D. Karp, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Siqing Fu, Cynthia E. Herzog, Aung Naing, David S. Hong, Shiraj Sen, Jason Roszik, Justin T. Moyers, Roberto Carmagnani Pestana
Purpose:Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44b2bbce2946a303e6ad0c658b3cbb82
https://doi.org/10.1158/1078-0432.c.6600059.v1
https://doi.org/10.1158/1078-0432.c.6600059.v1
Autor:
Vivek Subbiah, Funda Meric-Bernstam, Richard Gorlick, Nelson Hamerschlak, Anthony P. Conley, Joseph A. Ludwig, Neeta Somaiah, J. Andrew Livingston, Shreyaskumar R. Patel, Christina L. Roland, Valerae O. Lewis, Douglas J. Harrison, Jonathan B. Gill, Najat Daw, Wei-Lien Wang, Alexander J. Lazar, Robert S. Benjamin, Vinod Ravi, Ravin Ratan, Maria A. Zarzour, Shubham Pant, Apostolia M. Tsimberidou, Daniel D. Karp, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Siqing Fu, Cynthia E. Herzog, Aung Naing, David S. Hong, Shiraj Sen, Jason Roszik, Justin T. Moyers, Roberto Carmagnani Pestana
Summary of response outcomes across subgroups
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7f75586d0c115b6f39ae8a9adfd5e4
https://doi.org/10.1158/1078-0432.22634417
https://doi.org/10.1158/1078-0432.22634417
Autor:
Richard Gorlick, Edward A. Kolb, Malcolm A. Smith, Gregory Gatto, Stephen Erickson, Beverly Teicher, Douglas J. Harrison, Jonathan B. Gill, Wendong Zhang, Yifei Wang, Michael E. Roth, Pooja Hingorani
Membrane protein leucine–rich repeat containing 15 (LRRC15) is known to be expressed in several solid tumors including osteosarcoma. ABBV-085, an antibody–drug conjugate against LRRC15, conjugated to monomethyl auristatin E (MMAE), was studied in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0363e19c141dfbc766c3853a944bc1e7
https://doi.org/10.1158/1535-7163.c.6542836
https://doi.org/10.1158/1535-7163.c.6542836
Autor:
Richard Gorlick, Edward A. Kolb, Malcolm A. Smith, Gregory Gatto, Stephen Erickson, Beverly Teicher, Douglas J. Harrison, Jonathan B. Gill, Wendong Zhang, Yifei Wang, Michael E. Roth, Pooja Hingorani
Model Name, passage#, and time from implantation to testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::073846e1203289bb8d5e11a7abb726b5
https://doi.org/10.1158/1535-7163.22520929
https://doi.org/10.1158/1535-7163.22520929